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Objective: To survey the level and patterns of reverse transcriptase-based drug resistance
and subtype distribution among antiretroviral-treated HIV-infected patients receiving only
reverse transcriptase inhibitors in Iran.
Methods: A total of 25 samples of antiretroviral therapy experienced patients with no
history of using protease inhibitors were collected. After RNA extraction, reverse
transcriptase-nested PCR was performed. The ﬁnal products were sequenced and then
analysed for drug-resistant mutations and subtypes.
Results: No drug resistant mutations were observed among the 25 subjects. The results
showed the following subtypes among patients: CRF 35_AD (88%), CRF 28_BF (8%),
and CRF 29_BF (4%).
Conclusions: A signiﬁcant increase in drug resistance has been noted in recently-
infected patients worldwide. Subtype distributions are needed to perform properly-
designed surveillance studies to continuously monitor rates and patterns of transmitted
drug resistance and subtypes to help guide therapeutic approaches and limit transmission
of these variants.1. Introduction
The use of combinations of three or more antiretroviral drugs
from two drug classes has proven remarkably effective in con-
trolling the progression of HIV and has reduced mortality in
HIV-infected individuals [1]. These beneﬁts can be compromised
by the development of transmitted HIV-1 drug resistance. This
type of resistance is the consequence of mutations that emerge in
the viral proteins targeted by antiretroviral agents [2–9].
The implementation of antiretroviral therapy (ART) more
than a decade ago has improved the quality and life expectancy
of HIV-infected patients. Factors such as low-adherence rates bypatients, inappropriate ART regimens, incorrectly-prescribed
drugs, extensive genetic variation, toxicity of medication, high
pill burden, and HIV genomic mutations as the main cause of
virological and treatment failure have led to the emergence and
subsequent spread of antiviral drug resistance in HIV-infected
patients [5,10–15]. Surveillance studies have shown that
approximately 10% of new HIV-1 infections involve drug-
resistant strains, indicating that treated individuals are involved
in the spread of new infections. It has also been shown that
individuals infected de novo with drug-resistant viruses can
serve as a source of subsequent infection and contribute to the
spread of drug-resistant HIV [16].
The increase in the prevalence of transmitted drug resistance
in low- and middle-income countries varies by area according to
the nature of the ART programs implemented. This justiﬁes the
need for HIV-1 genotyping resistance testing before the initia-
tion of ART to monitor antiretroviral treatment of HIV-1 pa-
tients as a major factor for therapeutic regimens selection
[3,10,17–19]. Sequence analysis of the HIV-1 pol gene provides
important information about antiretroviral drug resistance-
associated mutations affecting the susceptibility of HIV-1article under the CC BY-NC-ND license (http://
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and on subtype diversity [20]. The present study surveyed the
level and patterns of PR-based drug resistance and subtype
distribution among antiretroviral-treated HIV-infected patients
who receive only RT inhibitors in Iran.
2. Materials and methods
2.1. Sample collection
This cross-sectional study examined 25 HIV-infected patients
undergoing ART at the Iranian Research Centre for HIV/AIDS
of Imam Khomeini Hospital in Tehran, Iran. All patients
received a combination of ART apart from PR inhibitors. A total
of 25 individuals were enrolled in the study (100% participa-
tion). The study protocol was approved by the Medical Research
Ethics Committee of Tarbiat Modares University in Tehran. All
participants provided written informed consent prior to sample
collection.
Initially, 5 mL blood samples were collected in ethyl-
enediaminetetraacetic acid blood collection tubes. The plasma
was separated by centrifugation at 3000 r/min and frozen at
−70 C until use for RNA extraction. The HIV pol regions,
which include viral protease genes, were ampliﬁed and
sequenced to determine the subtype and antiretroviral-resistant
mutations.
2.2. HIV RNA extraction and cDNA synthesis
HIV RNA was extracted from 140 mL of plasma using the
column puriﬁcation method (QIAamp Viral RNA Mini Kit,
Qiagen, Germany) according to manufacturer instructions.
Following RNA viral denaturation at 70 C for 10 min, cDNA
synthesis was performed at 42 C for 1 h using 200 IU of M-
MuLV reverse transcriptase (Fermentas) and 2 mL of antisense
outer primers (Table 1) plus 2 mL dNTP and 0.5 mL RNAse
inhibitor (Fermentas).
2.3. Nested PCR ampliﬁcation
First-round PCR was performed using 5 mL cDNA, 1 × PCR
buffer, 0.5 mL of 10 mmol/L dNTP, Pfu polymerase, 0.75 mL
50 mmol/L MgCl2, 0.5 mmol/L of 10 pmol/mL primer solution
containing outer primers (Table 1), and 15 mL of double-distilled
water. Brieﬂy, the ampliﬁcation proﬁle consisted of denaturation
at 95 C for 5 min, followed by 30 cycles of denaturation at
94 C for 50 s, annealing at 58 C for 40 s, extension at 72 C
for 50 s, followed by a ﬁnal extension phase at 72 C for 5 min.Table 1
The sequence of primers.
Primer Sequence Product
length
External
reverse
TGCCCTATYTCTAARTCAGATCC 586 bp
External
forward
TTAGYCCTATTGARACTGTACCAG
Internal
reverse
AATATTGCYGGTGAYCCTTTCCATC 324 bp
Internal
forward
GCCTGAAAATCCATYCAAYACTCCAn aliquot (about 2.5 mL) of the primary PCR product was used
for 35 cycles of nested PCR as follows: initial denaturation at
95 C for 5 min, 20 cycles of denaturation at 94 C for 50 s,
annealing at 58 C for 40 s, and polymerization at 72 C for 50 s,
with a ﬁnal elongation at 72 C for 5 min. An Eppendorf
gradient PCR system thermal cycler was used for all PCR re-
actions. The results were checked by electrophoresis of the
nested PCR products on 1.5% agarose gel and visualized with
ethidium bromide under UV light.2.4. Puriﬁcation and DNA sequencing
The PCR products were puriﬁed using a gel puriﬁcation kit
(Bioneer, Global Genomics Partner) according to manufacturer
instructions and sequenced on both strands (bi-directionally)
using the dideoxy chain termination method (ABI PRISM 3700
DNA Analyser Automated Sequencer, Applied Biosystems,
USA).3. Results
At the time of the study, the plasma samples were selected
retrospectively from 25 ART patients attending the Iranian
Research Centre for HIV/AIDS at Imam Khomeini Hospital in
Tehran in Iran. Of these, 19 (76%) were males and 6 (24%) were
females. The primary routes of HIV/AIDS transmission were
intravenous drug use (80%) and sexual contact (20%).
All 25 patients received highly active antiretroviral therapy
for at least 1 year. The therapy regimen contained nucleoside
reverse transcriptase inhibitor and non-nucleoside reverse tran-
scriptase inhibitor. None of the patients had experienced the use
of protease inhibitors (PIs). The CD4 cell count was below 250–
300 cells/m3. In all isolates, the PR segment of the pol gene
ampliﬁed and produced useful sequences in this region. Phylo-
genetic analysis of the PR sequences derived from all isolates
revealed no drug resistant mutations associated with the PIs.
In this study, recombinant CRF 35_AD (88%) was found to
be the predominant HIV subtype, followed by subtypes CRF
28_BF in 8% and CRF 29_BF in 4% of patients failing treat-
ment in Tehran. It was found that subtype CRF 35_AD of HIV
was the most prevalent among HIV-infected patients in Iran.
This study also showed that the major route of HIV/AIDS
transmission was through injection drug users in Iran.4. Discussion
The number of adults living with HIV in Iran was estimated
to be 26125 at the end of 2012 and was comprised of 89.8%
males and 10.2% females [21]. Most participants were
intravenous drug addicts, which is in accordance with results
of recent studies from different areas of Iran [22].
This study focused on mutations of the PR gene that confer
resistance to ART drugs in patients not previously treated with
PIs. The prevalence of transmitted PR resistance-associated
mutations in the sample of 25 patients receiving ART in Teh-
ran was investigated and it was found that none of the ART
patients had major resistance mutations. This is in agreement
with global studies showing minimal prevalence of antiretroviral
drug resistance in individuals experiencing ART [23–25].
No major mutations associated with drug resistance were
observed in this study, although other studies performed in Iran
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Previous studies on the prevalence of transmission of drug-
resistant HIV found the prevalence to be as follows: North
America (12.9%), Europe (10.9%), Latin America (6.3%), Af-
rica (4.7%), and Asia (4.2%) [29].
Previous studies have indicated that subtypes A1 and B are
most prevalent in Iranian HIV-positive patients [10,30,31]. The
present study found recombinant CRF 35_AD (88%) to be the
predominant HIV subtype, followed by subtypes CRF 28_BF
in 8% and CRF 29_BF in 4% of patients failing treatment in
Tehran, which is consistent with other reports of HIV in Iran
[3,32–35]. The results support recent ﬁndings on the emergence
of new predominant HIV subtypes/CRFs, demonstrating the
dynamic and rapid evolution of HIV. Recombinants are
currently estimated to be responsible for at least 20% of HIV-
1 infections worldwide [36,37].
There is no compelling evidence that the HIV-1 subtype
should be considered during the choice of ART regimens for
ﬁrst-line or second-line therapy. Consideration of cost, effec-
tiveness, toxicity, and tolerability are more important in low-
income and middle-income countries [34].
The signiﬁcant increase in drug resistance in recently-
infected HIV patients and subtype distribution requires perfor-
mance of properly-designed surveillance studies to continuously
monitor rates and patterns of transmitted drug resistance and
subtypes to help guide therapeutic approaches and limit trans-
mission of these variants.
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